Isatin-benzoazine Molecular Hybrids As Potential Antiproliferative Agents: Synthesis and in Vitro Pharmacological Profiling

Overview

Journal Drug Des Devel Ther

Specialty Pharmacology

Date 2017 Aug 30

PMID 28848327

Citations 24

Authors

Hatem A Abdel-Aziz

Wagdy M Eldehna

Adam B Keeton

Gary A Piazza

Adnan A Kadi

Mohamed W Attwa

Ali S Abdelhameed

Mohamed I Attia

Affiliations

Soon will be listed here.

Abstract

In continuation of our endeavor with respect to the development of potent and effective isatin-based anticancer agents, we adopted the molecular hybridization approach to design and synthesize four different sets of isatin-quinazoline ( and )/phthalazine ()/quinoxaline () hybrids. The antiproliferative activity of the target hybrids was assessed towards HT-29 (colon), ZR-75 (breast) and A-549 (lung) human cancer cell lines. Hybrids emerged as the most active antiproliferative congener in this study. Compound induced apoptosis via increasing caspase 3/7 activity by about 5-fold in the A-549 human cancer cell line. In addition, it exhibited an increase in the G1 phase and a decrease in the S and G2/M phases in the cell cycle effect assay. Furthermore, it displayed an inhibitory concentration 50% value of 9.5 µM against multidrug-resistant NCI-H69AR lung cancer cell line. The hybrid was also subjected to in vitro metabolic investigations through its incubation with rat liver microsomes and analysis of the resulting metabolites with the aid of liquid chromatography-mass spectrometry.

Citing Articles

Investigation of Newly Synthesized Fluorinated Isatin-Hydrazones by Antiproliferative Activity, Molecular Docking, ADME Analysis, and e-Pharmacophore Modeling.

Basaran E, Kopru S, Akkoc S, Turkmenoglu B ACS Omega. 2024; 9(24):26503-26518.

PMID: 38911768 PMC: 11191101. DOI: 10.1021/acsomega.4c03014.

Design, synthesis, molecular modelling and biological evaluation of novel 6-amino-5-cyano-2-thiopyrimidine derivatives as potent anticancer agents against leukemia and apoptotic inducers.

Ahmed N, Mohamed M, Awad S, El-Hameed R, El-Tawab N, Gaballah M J Enzyme Inhib Med Chem. 2024; 39(1):2304625.

PMID: 38348824 PMC: 10866072. DOI: 10.1080/14756366.2024.2304625.

Nitrogen Containing Heterocycles as Anticancer Agents: A Medicinal Chemistry Perspective.

Kumar A, Singh A, Singh H, Vijayan V, Kumar D, Naik J Pharmaceuticals (Basel). 2023; 16(2).

PMID: 37259442 PMC: 9965678. DOI: 10.3390/ph16020299.

1-Benzyl-5-bromo-3-hydrazonoindolin-2-ones as Novel Anticancer Agents: Synthesis, Biological Evaluation and Molecular Modeling Insights.

Al-Warhi T, Almahli H, Maklad R, Elsayed Z, El Hassab M, Alotaibi O Molecules. 2023; 28(7).

PMID: 37049966 PMC: 10096524. DOI: 10.3390/molecules28073203.

Development of novel isatin thiazolyl-pyrazoline hybrids as promising antimicrobials in MDR pathogens.

Al-Warhi T, Elimam D, Elsayed Z, Abdel-Aziz M, Maklad R, Al-Karmalawy A RSC Adv. 2022; 12(48):31466-31477.

PMID: 36382148 PMC: 9629177. DOI: 10.1039/d2ra04385h.

References

Sun L, Liang C, Shirazian S, Zhou Y, Miller T, Cui J . Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor.... J Med Chem. 2003; 46(7):1116-9. DOI: 10.1021/jm0204183. View

Roth G, Heckel A, Colbatzky F, Handschuh S, Kley J, Lehmann-Lintz T . Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120). J Med Chem. 2009; 52(14):4466-80. DOI: 10.1021/jm900431g. View

Meunier B . Hybrid molecules with a dual mode of action: dream or reality?. Acc Chem Res. 2007; 41(1):69-77. DOI: 10.1021/ar7000843. View

Quaroni A, Wands J, Trelstad R, Isselbacher K . Epithelioid cell cultures from rat small intestine. Characterization by morphologic and immunologic criteria. J Cell Biol. 1979; 80(2):248-65. PMC: 2110349. DOI: 10.1083/jcb.80.2.248. View

Prenen H, Cools J, Mentens N, Folens C, Sciot R, Schoffski P . Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate. Clin Cancer Res. 2006; 12(8):2622-7. DOI: 10.1158/1078-0432.CCR-05-2275. View

Krug M, Hilgeroth A . Recent advances in the development of multi-kinase inhibitors. Mini Rev Med Chem. 2008; 8(13):1312-27. DOI: 10.2174/138955708786369591. View

Ramshid P, Jagadeeshan S, Krishnan A, Mathew M, Nair S, Pillai M . Synthesis and in vitro evaluation of some isatin-thiazolidinone hybrid analogues as anti-proliferative agents. Med Chem. 2010; 6(5):306-12. DOI: 10.2174/157340610793358909. View

Thornton K, Kim G, Maher V, Chattopadhyay S, Tang S, Moon Y . Vandetanib for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease: U.S. Food and Drug Administration drug approval summary. Clin Cancer Res. 2012; 18(14):3722-30. DOI: 10.1158/1078-0432.CCR-12-0411. View

Kaminskyy D, Khyluk D, Vasylenko O, Zaprutko L, Lesyk R . A facile synthesis and anticancer activity evaluation of spiro[thiazolidinone-isatin] conjugates. Sci Pharm. 2011; 79(4):763-77. PMC: 3221502. DOI: 10.3797/scipharm.1109-14. View

10.

Caldwell G . Compound optimization in early- and late-phase drug discovery: acceptable pharmacokinetic properties utilizing combined physicochemical, in vitro and in vivo screens. Curr Opin Drug Discov Devel. 2009; 3(1):30-41. View

11.

Deeks E . Olaparib: first global approval. Drugs. 2015; 75(2):231-40. DOI: 10.1007/s40265-015-0345-6. View

12.

McCormack P . Nintedanib: first global approval. Drugs. 2014; 75(1):129-39. DOI: 10.1007/s40265-014-0335-0. View

13.

Havrylyuk D, Kovach N, Zimenkovsky B, Vasylenko O, Lesyk R . Synthesis and anticancer activity of isatin-based pyrazolines and thiazolidines conjugates. Arch Pharm (Weinheim). 2011; 344(8):514-22. DOI: 10.1002/ardp.201100055. View

14.

Abdel-Aziz H, Elsaman T, Al-Dhfyan A, Attia M, Al-Rashood K, Al-Obaid A . Synthesis and anticancer potential of certain novel 2-oxo-N'-(2-oxoindolin-3-ylidene)-2H-chromene-3-carbohydrazides. Eur J Med Chem. 2013; 70:358-63. DOI: 10.1016/j.ejmech.2013.09.060. View

15.

Solomon V, Hu C, Lee H . Hybrid pharmacophore design and synthesis of isatin-benzothiazole analogs for their anti-breast cancer activity. Bioorg Med Chem. 2009; 17(21):7585-92. DOI: 10.1016/j.bmc.2009.08.068. View

16.

Billings R . Sex differences in rats in the metabolism of phenytoin to 5-(3,4-dihydroxyphenyl)-5-phenylhydantoin. J Pharmacol Exp Ther. 1983; 225(3):630-6. View

17.

Wang S, Zhao Y, Zhang G, Lv Y, Zhang N, Gong P . Design, synthesis and biological evaluation of novel 4-thiazolidinones containing indolin-2-one moiety as potential antitumor agent. Eur J Med Chem. 2011; 46(8):3509-18. DOI: 10.1016/j.ejmech.2011.05.017. View

18.

Havrylyuk D, Zimenkovsky B, Vasylenko O, Gzella A, Lesyk R . Synthesis of new 4-thiazolidinone-, pyrazoline-, and isatin-based conjugates with promising antitumor activity. J Med Chem. 2012; 55(20):8630-41. DOI: 10.1021/jm300789g. View

19.

Cohen M, Johnson J, Chen Y, Sridhara R, Pazdur R . FDA drug approval summary: erlotinib (Tarceva) tablets. Oncologist. 2005; 10(7):461-6. DOI: 10.1634/theoncologist.10-7-461. View

20.

Ibrahim H, Abou-Seri S, Ismail N, Elaasser M, Aly M, Abdel-Aziz H . Bis-isatin hydrazones with novel linkers: Synthesis and biological evaluation as cytotoxic agents. Eur J Med Chem. 2015; 108:415-422. DOI: 10.1016/j.ejmech.2015.11.047. View